| ATPC 0.1253 79.00% | MTEN 0.0327 -7.37% | OCG 0.01 -15.25% | SOXS 2.08 -8.77% | AUID 2.035 105.04% | IVP 0.0515 -37.20% | CJMB 3.5694 218.70% | ZSL 3.045 8.17% | SLV 81.5 -3.62% | NVDA 188.1886 2.76% | APLT 0.1018 1.90% | SPHL 8.9182 296.36% | INTC 48.34 -0.78% | BNKK 4.6418 66.97% | SOXL 60.565 9.36% | TQQQ 55.5586 3.21% | DVLT 0.7554 5.18% | ASST 0.9847 -4.40% | BYND 1.02 6.04% | TSLL 18.48 2.27% | SIDU 3.675 -2.00% | EEM 58.15 0.69% | JTAI 0.4798 5.54% | AMD 236.8512 5.93% | TZA 5.985 -2.84% | TSLS 5.125 -1.25% | ONDS 13.065 -3.65% | MSTX 4.745 -8.75% | PTHL 0.4676 6.32% | NOK 6.6459 4.50% | PCLA 0.2119 -4.12% | TSM 346.17 5.83% | IBRX 3.3386 10.55% | SEGG 1.0804 16.59% | RZLV 4.653 14.61% | VALE 14.675 0.44% | SPY 694.59998 0.61% | GRAB 4.48 -3.24% | IBIT 54.3599 -1.95% | QQQ 626.23 1.08% | BBAI 6.285 0.40% | SQQQ 64.8096 -3.18% | GPUS 0.3055 -4.80% | OCUL 11.05 -0.18% | XLF 54.63 0.89% | CRWV 97.83 8.94% | DUST 5.795 -0.09% | TSLA 444.3829 1.18% | BMNR 31.59 -3.26% | EVTV 3.5233 13.65%

JPMorgan Upgrades Kodiak Sciences To Neutral, Sees Catalyst-Heavy Period Ahead

JPMorgan upgraded Kodiak Sciences (NASDAQ:KOD) from Underweight to Neutral and set a December 2026 price target of $15.00.

The bank said Kodiak is entering a catalyst-rich period over the next two years, with pivotal trial data expected for tarcocimab, KSI-501, and KSI-101. While acknowledging that valuation is not a barrier to a more positive stance, JPMorgan noted that investor sentiment remains mixed and that clear clinical wins may be required to shift views more favorably.

The firm sees Kodiak shares performing in line with the broader biotech sector until further clarity emerges from these upcoming data releases.

Published on: August 14, 2025